The identification of a patient with a rare form of severe dysbetalipoproteinemia allowed the study of the consequences of total absence of apolipoprotein E (apoE).
the presence of other genetic and/or environmental factors being necessary for development of dysbetalipoproteinemia. Cases of apoE deficiency have been reported, 4-9 but none included neurocognitive or retinal function studies. Next-generation DNA sequencing produces abundant, short, inexpensive reads (25-500 base pairs [bp] ). 10 Wholeexome sequencing was undertaken in an exceptionally severe case of dysbetalipoproteinemia to understand the molecular basis. Structural and compositional effects on lipoproteins were studied. Because apoE is believed to play a critical role in brain function 11 and is expressed in the central nervous system and retinal pigment epithelium, 12 extensive studies of retinal and neurocognitive function were performed.
Methods

Participants
A 40-year-old African American man was referred to the Lipid Clinic, University of California, San Francisco, with severe hyperlipidemia relatively unresponsive to statin and fibrate treatment. He had large tuberous xanthomas (Figure 1 ), especially on his elbows, knees, and ankles, Achilles tendon xanthomas, morbilliform xanthomas on his ears, alae nasae, and volar aspects of his hands and feet, and planar xanthomas on his gluteal region. Xanthomas were present on dorsal aspects of his hands over proximal and distal interphalangeal joints and metacarpophalangeal joints. Xanthomas first appeared at age 6 years. His body mass index (calculated as weight in kilograms divided by height in meters squared) was 30.4. He had been treated for modest hypertension, never smoked or used illicit drugs, and was not drinking alcohol. His diet, generally low in fat, contained little saturated and no trans fats and was low in rapidly absorbed carbohydrates. He had no signs or symptoms of neurological deficit, ophthalmological disease, or cardiovascular disease (CVD). He did not start talking until age 3 years. At school, he performed better in mathematics than reading, finishing 11th grade with a C+/B− average. His parents and 4 maternal half siblings have no evidence of CVD. His father, not available for study, is known to be well and to have a normal lipid panel. The patient has 3 healthy children aged 4, 5, and 7 years. They and his 57-year-old mother have no xanthomas. Written informed consent was obtained from participants for DNA isolation and plasma collection. Children were included with parental consent. The University of Cali- 
Next-Generation Sequencing
We extracted DNA from blood using the Puregene kit (Qiagen). An Illumina TruSeq Exome Enrichment kit was used for library preparation and exome capture. The captured library was amplified with 10 polymerase chain reaction cycles and sequenced using an Illumina HiSeq 2000 sequencer. Paired 100-bp end reads (54 million reads) were generated (mean coverage ×61) on targeted regions (89% covered by ≥10 reads). Raw FASTQ data were aligned to the reference genome (hg19) by Burrows-Wheeler Aligner. 13 Sequence Alignment/Map (SAM) files were converted to SAM Binary (BAM) files with SAMtools, 14 sorted, marked for duplicates, and indexed with Picard (http: //picard.sourceforge.net). Base quality score recalibration, local realignment, and duplicate removal were performed with Genome Analysis Toolkit. 15, 16 Single-nucleotide polymorphisms and indels were called by Genome Analysis Toolkit and quality filters were applied as recommended. The variant list was annotated and further filtered using summarize_an-novar.pl from ANNOVAR. 17 Rare and deleterious exonic variants were identified using the following filters: keep exonic or splicing variants, remove synonymous variants, remove variants not conserved and in segmental duplication regions, remove common variants (1000 Genomes Project; minor allele frequency >0.05), and keep damaging variants (Sorting Intolerant From Tolerant score <0.05). A list of 432 genes or loci (eTable 1 in the Supplement) related to lipid metabolism was compiled.
Lipoprotein Analysis
Blood was drawn from the patient, his mother, and a normolipidemic male participant after overnight fasting. Lipoprotein fractions were prepared from plasma by sequential ultracentrifugation. 18 Cholesterol and TG contents were determined by automated chemical analysis. After negative staining with 2% potassium phosphotungstate, pH 6.5, using the drop method, 19 lipoproteins were examined by electron microscopy at 80 kV in a JEOL 1230 electron microscope (JEOL USA, Inc) and photographed with a Gatan Ultrascan USC1000 camera (Gatan Inc), and particle diameters were measured using ImageJ64 (http://rsbweb.nih.gov/ij/index.html). Blood was also obtained from the patient's wife and 2 daughters.
Plasma from the patient and 8 control participants was analyzed using a Lipoprint high-density lipoproteins (HDL) subfractions kit (Quantimetrix). Nondenaturing 2-dimensional gradient gel electrophoresis followed by apoA-I immunoblotting was performed on plasma from the patient and 17 control participants.
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Lipoproteins were precipitated with ethanol and diethyl ether (3:1) and centrifuged. Pellets dissolved in 10% sodium dodecyl sulfate were run on 4% to 20% sodium dodecyl sulfatepolyacrylamide gel electrophoresis. Gels were stained with Coomassie Brilliant Blue R-250 or electrotransferred to nitrocellulose membranes. Following blocking, membranes were incubated with the appropriate antibody. Secondary antibodies were horseradish peroxidase linked. Blots were incubated with SuperSignal West Pico (Pierce). Chemiluminescence was detected using a ChemiDoc XRS+ imager (BioRad). Richard J. Havel, MD, University of California, San Francisco, provided apoB-100, apoE, and apoC-IV antibodies.
21-23 The apoC-III goat antibody was ab27624 from Abcam. A trpE/apoA-IV fusion protein was generated to produce a goat antibody to human apoA-IV. The apoA-I antibody has been described.
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Cerebrospinal Fluid Analysis
Cerebrospinal fluid was obtained by lumbar puncture after an overnight fast. β-Amyloid 1-42 (Aβ42) and total tau protein levels were determined using the multiarray Aβ ultrasensitive kit and total tau kit, respectively (Meso Scale Discovery). Levels of tau phosphorylated at threonine 181 (P-tau 181 ) were measured using the Innotest Phospho-Tau (181P) kit (Innogenetics). For Aβ42 and P-tau 181 , undiluted cerebrospinal fluid was used. For total tau, it was diluted 4-fold. Normalization for plate-to-plate variation used reference samples provided by Kaj Blennow, MD, PhD, University of Gothenburg, Gothenburg, Sweden.
Results
Visual Examination
Visual function was normal by all tests. Foveal sensitivity and visual fields were normal bilaterally. Color vision was mildly abnormal, revealing a total color difference score of 193.5 OD and 168.3 OS with a color confusion index of 1.65 OD and 1.44 OS, consistent with mild tritanomaly or tritanopy affecting all 3 cone classes. 25 The Arden ratio was normal, indicating normal retinal pigment epithelial depolarization in response to light. Recovery of dark-adapted visual sensitivity after exposure to bright light was normal, with normal cone thresholds, normal timing of the cone-rod break, and normal final rodmediated thresholds. The retinal structure was normal, including retinal lamination and layer thickness throughout the central 20°of the macula in each eye. Fundus autofluorescence images were normal in the right eye but showed a single, small hyperautofluorescent spot corresponding to a white subretinal lesion on the color fundus photograph in the left eye. This finding could represent local evidence of abnormal lipid accumulation in or beneath the retinal pigment epithelium.
Cardiovascular Examination
Baseline electrocardiographic findings were normal. On treadmill stress testing (standard Bruce protocol), 2-to 3-mm upsloping ST depressions at peak stress that resolved to the baseline level during recovery were noted. This suggests, but is not diagnostic for, exercise-induced ischemia at high workload and high double product. Table 1 . For the patient, the bulk of the plasma cholesterol and TG was found in VLDL. The ratios of both total and unesterified cholesterol to TG were considerably higher in the patient's VLDL than in the other samples. This was not observed in the other lipoproteins. In the patient's and his mother's LDL, both ratios were lower than in the control. The ratio of core lipid (TG plus cholesteryl esters) to protein was much higher for the patient's VLDL compared with his mother and a control participant (5.6 vs 1.9 and 2.1, respectively). It was also considerably higher in the patient's intermediate-density lipoprotein (IDL) (3.5 vs 1.6 and 1.7, respectively) but not in LDL or HDL. The patient's IDL total lipid content was much less than in VLDL, although it was higher than in the other samples. The patient's LDL cholesterol level was low compared with the other samples. His levels of VLDL, IDL, and LDL are characteristic of severe dysbetalipoproteinemia. There were no profound differences in HDL.
Coomassie-stained sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed considerable amounts of apoB-48 in the patient's VLDL, IDL, and LDL with trace amounts in the other samples (eFigure 1 in the Supplement). No apoB-48 was seen in the HDL fractions (data not shown). A significant amount of apoA-IV was seen in the patient's VLDL, less in IDL, and a trace in LDL. Apolipoprotein A-I was seen in his VLDL, IDL, and LDL. There was no apoE in his lipoproteins. The level of apoE in his mother's VLDL and IDL was about half that in the control. An immunoblot of the patient's plasma showed an absence of apoE. His 2 daughters had about half the normal levels (eFigure 2 in the Supplement). Immunoblots confirmed the presence of high amounts of apoA-I and apoA-IV in the patient's VLDL, IDL, and LDL (Figure 2) . Particularly striking was the much higher amount of apoA-IV in VLDL and of apoA-I in LDL. There were decreased amounts of apoC-III and apoC-IV in VLDL compared with the control. The mother's VLDL showed intermediate levels. Immunoblots showed no apoE in the patient's fractions and reduced levels in his mother's VLDL and IDL compared with the control (Figure 2) . No truncated apoE species were detected.
HDL Analysis
The patient's plasma showed an abnormal HDL size distribution (Figure 3) with fewer large particles (fractions 1, 2, and 3), totaling 45% of the HDL-C compared with a mean (SE) of 70.0% for control participants. There was a higher percentage of intermediate-sized particles (fractions 4, 5, 6, and 7), comprising 38% of total HDL-C compared with a mean (SE) of 26.5% (1.5%) for control participants. These Lipoprint data were complemented by the 2-dimensional apoA-I immunoblot (eFigure 3 in the Supplement) showing elevated levels of prebeta-1 HDL. Quantitation by densitometry revealed a level of 22 mg/dL compared with a mean (SE) of 7 (0.6) mg/dL for control participants (n = 17).
Electron Microscopy
Electron microscopy revealed that particles in the patient's VLDL were normal in appearance ( Figure 4B ) and particle diameter (eFigure 4 and eTable 2 in the Supplement). His IDL, displaying normal diameters, contained some large lamellar particles having electron-opaque cores attached to electronlucent zones often surrounded by membranes ( Figure 4D ). These lamellar structures were also seen in LDL ( Figure 4F ). A notable difference in LDL was a bimodal size distribution, although the overall mean and median diameters were similar to those in control participants. No HDL abnormalities were observed.
Exome Sequencing Results
To identify mutations causing the severe dysbetalipoproteinemia phenotype, we performed whole-exome sequencing and identified 645 rare and deleterious variants. Further filtering against lipid metabolism pathway genes yielded 9 variants ( Table 2) . A homozygous 1-bp frameshift deletion was identified in APOE exon 4 (c.291delG, p.E97fs) at chr19: 45411844 (GenBank NT_011109.16), predicting a change of residues 97 and 98 followed by a stop codon. Sanger sequencing confirmed the The abnormal composition of apolipoproteins (apo) in the lipoprotein fractions from the patient (P) is compared with the compositions of his mother (M) and a normolipidemic control participant (C). Equal amounts (20 μg) of total protein were run in each lane. Six antibodies were used against the following: apoB-100, apoA-IV, apoE, apoA-I, apoC-IV, and apoC-III. IDL indicates intermediate-density lipoprotein; LDL, low-density lipoprotein; and VLDL, very low-density lipoprotein.
Discussion
We identified a novel 1-bp homozygous APOE frameshift deletion leading to apoE deficiency in a patient with severe dysbetalipoproteinemia. Exome sequencing proved valuable as other functionally damaging variants were identified in genes involved in lipid metabolism, providing clues to additional factors possibly contributing to the phenotype. A neurological examination showed no evidence of neurodegenerative disease. Neuropsychological testing was essentially unremarkable, without any progressive concerns for cognitive decline or behavioral change. One notable exception pertains to neurodevelopment that reveals some learning disability, possibly dyslexia, given the history of delayed speech. It is unknown what effects his dyslipidemia may have on overall cognitive performance. The possible learning disability would be expected to have the greatest impact on the interpretation of results of cognitive testing. In general, patients with histories of learning disabilities such as dyslexia often have other untested strengths including excellent social and interpersonal skills, which this patient clearly possesses. Overall, he displayed intact global performance as evidenced by his Mini-Mental State Examination score. However, on subdomain tests, he had difficulties in multiple domains including memory, language, visuospatial abilities, and executive functions. Despite this, his functional status was intact and considered to be clinically normal. Further supporting this, brain imaging showed no pattern of atrophy or burden of white matter disease. The cerebrospinal fluid content of Aβ42 and tau proteins was normal.
An 11.3-kDa truncated apoE protein, predicted by the APOE mutation (p.E97fs), was absent in plasma and lipoproteins. The apoE ligand domain for the LDLR would be missing as would the C-terminal domain, which binds lipid and promotes tetramer formation. Apolipoprotein E, synthesized in liver and intestine, is essential for chylomicron and VLDL processing. As the TG cores are hydrolyzed, additional apoE is acquired. Resulting remnants pass the liver sieve 30 and enter the space of Disse, gaining additional apoE before uptake via the LDLR, LDLR-related protein, and heparin sulfate proteoglycan. 1 Apolipoprotein E is also involved in converting some VLDL remnants, via LIPC (lipase, hepatic), to LDL. The level of VLDL cholesterol seen here was considerably higher than seen in typical dysbetalipoproteinemia associated with ε2/ε2 homozygosity. The mean (SD) ratio of cholesterol to TG in VLDL is 0.53 (0.18) (n = 45) (C. R. Pullinger, PhD, and J. P. Kane, MD, PhD, unpublished data, 1989-2014). Therefore, the ratio of 1.52 in our patient is exceptionally high.
The increased amounts of apoA-IV in VLDL and IDL we observed were seen in other reports of apoE deficiency 4,5,9 and in apoE-deficient mice. 31 We additionally found apoA-IV in LDL.
Increased amounts of apoA-I were observed in LDL from an High-density lipoprotein (HDL) subfractions from the patient are compared with 5 representative control samples, measured as the scanned density of Sudan black-stained lipids. There is an abnormal HDL size distribution compared with control samples, with the patient's HDL having a much higher proportion of small particles (fractions 8, 9, and 10). There is some increase in medium-sized particles (fractions 4, 5, 6, and 7). There is a correspondingly lower percentage in the largest particles (fractions 1, 2, and 3). LDL indicates low-density lipoprotein; VLDL, very low-density lipoprotein.
mice. 31 The association of apoE deficiency with decreased apoC-III and apoC-IV in VLDL is novel. Abnormal lamellar lipoprotein particles similar to those we observed were seen in electron micrographs of IDL and LDL from apoE and lipc doubly deficient mice. 32 These particles with electron-opaque cores and electron-lucent zones were thought to arise in the absence of lipc due to high amounts of β-VLDL. Apolipoprotein E-deficient mice exhibited less pronounced LDL lamellar particles. 32 The absence of lipc possibly exacerbates the process but is not a prerequisite. Notably, our patient is heterozygous for a potentially significant mutation in LIPC.
We observed a large increase in small HDL species in our patient's plasma, particularly prebeta-1 HDL, analogous to observations with ApoE knockout mice.
33 Prebeta-1 HDL levels positively associate with increased risk of new CVD events, 34 with ischemic heart disease, 35 and with both coronary artery disease and myocardial infarction. The alterations in lipoproteins in the absence of apoE are manifold. Accumulation of VLDL and remnants reflects absence of the ligand for hepatic uptake. The observed morphologic changes appear to reflect abnormal accumulation of polar constituents in surface monolayers of VLDL, chylomicrons, and their daughter particles, particularly LDL. Enrichment of apoA-IV and apoA-I in these particles, possibly replacing apoE, is notable. Deficiency of apoC-III and apoC-IV could promote instability of surface monolayers. The striking increase of prebeta-1 HDL, regarded as the quantum particle among HDL species, suggests that apoE may play heretofore unappreciated roles in the generation, interconversion, or removal of HDL species.
Given the severity of his dyslipidemia, extensive xanthomas, and high potential for premature CVD, strategies aimed at reducing the generation of chylomicrons and VLDL should be aggressively pursued. Low dietary fat intake and use of fibrates and/or niacin coupled with statin therapy usually control hyperlipidemia in dysbetalipoproteinemia but have been relatively ineffective in the management of this patient. Inhibitors of proprotein convertase subtilisin/kexin type 9 and microsomal triglyceride transfer protein, apoB antisense oligonucleotides, and enhancers of adenosine monophosphate kinase may be of additional benefit. Bone marrow transplantation corrects dyslipidemia in apoEdeficient mice 37 and might be considered in the face of severe CVD. Apolipoprotein E is expressed in the central and peripheral nervous systems. 38 Produced and secreted mainly by astrocytes, 39 it is believed to be important for normal brain function. Apolipoprotein E was thought not to cross the blood-brain barrier, with all found in the central nervous system synthesized locally. However, recent evidence indicates that apoE4 expression compromises the blood-brain barrier (as does apoE deficiency). 40 Studies of brain histology, neurodegenerative markers, cholinergic activity, and neuronal function in knockout mice have been equivocal. 39 Failure of detailed neurocognitive and retinal studies to demonstrate defects in our patient suggests either that the functions of apoE in the brain and eye are not critical or that they can be fulfilled by a surrogate protein. Surprisingly, with respect to central nervous system function, it appears that having no apoE is better than having the apoE4 protein. Thus, projected therapies aimed at reducing apoE4 in the brain could be of benefit in neurodegenerative disorders such as Alzheimer disease.
Conclusions
The molecular basis for the severe dyslipidemia in our patient was found to be homozygosity for an ablative APOE frameshift mutation (c.291del, p.E97fs). The absence of the apoE protein did not affect neurocognitive or retinal function.
